Stockreport

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results [Yahoo! Finance]

Pliant Therapeutics, Inc.  (PLRX) 
PDF Pliant Therapeutics, Inc. PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated d [Read more]